[Translation] Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PMS-001 after single and multiple intravenous injections in healthy adult subjects

研究受试药物PMS-001首次用于健康人体的安全性、耐受性以及药代动力学等药理学参数。

[Translation]

The study aims to investigate the pharmacological parameters such as safety, tolerability and pharmacokinetics of the test drug PMS-001 when used in healthy humans for the first time.

Start Date-

Sponsor / Collaborator

Qingdao Primedicine Pharmaceutical Technology Co., Ltd.

JPRN-jRCT2052200025 / CompletedPhase 2IIT

An exploratory Investigator Initiated clinical trial for the development of PMS-1, a device for objectively monitoring the efficacy of analgesics on postoperative pain

Start Date02 Sep 2020

Sponsor / Collaborator-

100 Clinical Results associated with PMS-001

100 Translational Medicine associated with PMS-001

100 Patents (Medical) associated with PMS-001

Literatures (Medical) associated with PMS-001

01 Jul 2020·Science of The Total EnvironmentQ2 · ENVIRONMENTAL SCIENCE & ECOLOGY

Co-treatment of potassium ferrate and peroxymonosulfate enhances the decomposition of the cotton straw and cow manure mixture

Q2 · ENVIRONMENTAL SCIENCE & ECOLOGY

Article

Author: Xing, Defeng ; Cui, Han ; Wang, Jing ; Liu, Bingfeng ; Cao, Guangli ; Xie, Guojun

Since there is high lignocellulose content in the cotton straw and cow manure mixture (MCC), the appropriate MCC pretreatment is important to promote the anaerobic digestion (AD) hydrolysis. This study mainly explored the effect of potassium ferrate (PF) and peroxymonosulfate (PMS) pretreatments on MCC decomposition. PMS + PF co-treatment showed a higher reduction of total solid and volatile solid than PF pretreatment and PMS pretreatment. Hydrolysis of treated MCC indicated that the PF pretreatment was more effective to the release of organics than the PMS pretreatment and the PMS + PF co-treatment. However, the PMS + PF co-treatment resulted in a higher lignin removal rate (40.4%-50.5%) than the PMS pretreatment (30.8%) and the PF pretreatment (21.4%). The PMS₁ + PF₂ co-treatment (molar ratio of 1:2) acquired the optimal lignin removal rate and the release of organics among the PMS + PF co-treatment with different dosing ratio. Potential mechanism was that PF reduction products activated PMS to produce free radicals (SO₄^-, OH), which attacked lignocellulosic components and promoted MCC decomposition. The PMS₁ + PF₂ co-treatment was deduced to be the optimal pretreatment method when considering MCC decomposition, biodegradability, and mass transfer in the bioreactor.

Anticancer research

Effects of a new clerodane diterpenoid isolated from propolis on chemically induced skin tumors in mice.

Article

Author: Sakamoto, S ; Kuwa, K ; Matsuno, T ; Nakayama, T ; Nagasawa, H ; Sassa, S ; Yoshimura, S ; Suzuki, S ; Mitamura, T ; Kudo, H ; Maemura, M

Propolis is a resinous material gathered by honey bees from the buds and bark of certain trees and plants, and used inside their hives. Characteristic components of propolis are many kinds of flavonoid aglycones. The methanol extract of a Brazilian propolis was fractionated by HPLC, and a tumoricidal substance was isolated and characterized as a new clerodane diterpenoid (PMS-1) with a molecular formula of C20H32O3 (MW: 320). We investigated the effects of PMS-1 on skin tumorigenesis and the development of skin tumors induced by 7,12-dimethylbenz(a)anthracene application on mouse back skin. It was tentatively concluded that PMS-1 reduced the incidence of skin tumors by inhibition of DNA synthesis in a de novo pathway, and suppressed the growth of the tumors by decreasing DNA synthesis in a salvage pathway.

100 Deals associated with PMS-001

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Ischemic Stroke	Phase 1	CN	Qingdao Primedicine Pharmaceutical Technology Co., Ltd.	06 Jun 2022
Alzheimer Disease	Preclinical	CN	Qingdao Primedicine Pharmaceutical Technology Co., Ltd.	30 Jan 2022
Depressive Disorder, Major	Preclinical	CN	Qingdao Primedicine Pharmaceutical Technology Co., Ltd.	30 Jan 2022
Unspecified drug dependence	Preclinical	CN	Qingdao Primedicine Pharmaceutical Technology Co., Ltd.	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

PMS-001

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation